177Lu-DGUL
Phase 3A PSMA-targeted radiopharmaceutical for metastatic castration-resistant prostate cancer; a 150-patient Korean Phase 3 was approved in September 2026 and conditional marketing approval has been applied for.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has applied for conditional approval of its prostate-cancer radiopharmaceutical and gained approval for a Korean Phase 3.
Roles often seen at this stageClinical & PV · Regulatory affairs · Medical & MSL
A developer of radiopharmaceuticals for cancer, whose lead prostate-cancer candidate is 177Lu-DGUL (poqubotide satetracetin).
A PSMA-targeted radiopharmaceutical for metastatic castration-resistant prostate cancer; a 150-patient Korean Phase 3 was approved in September 2026 and conditional marketing approval has been applied for.
Combination with MSD's checkpoint inhibitor Keytruda under a clinical collaboration and supply agreement signed in February 2025.
Received MFDS approval of the Korean Phase 3 trial plan for 177Lu-DGUL.
Applied to the MFDS for conditional marketing approval of 177Lu-DGUL.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.